BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1092 related articles for article (PubMed ID: 16364297)

  • 21. Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy.
    Yeh PT; Yang CM; Huang JS; Chien CT; Yang CH; Chiang YH; Shih YF
    Ophthalmology; 2008 Apr; 115(4):734-737.e1. PubMed ID: 18177940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
    Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H
    Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy.
    Limb GA; Hickman-Casey J; Hollifield RD; Chignell AH
    Invest Ophthalmol Vis Sci; 1999 Sep; 40(10):2453-7. PubMed ID: 10476819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
    Itakura H; Kishi S; Kotajima N; Murakami M
    Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Robo1 on retinal pigment epithelial cells and experimental proliferative vitreoretinopathy.
    Huang L; Xu Y; Yu W; Li Y; Chu L; Dong J; Li X
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3193-204. PubMed ID: 20071679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
    Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
    Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes.
    Tsanou E; Ioachim E; Stefaniotou M; Gorezis S; Charalabopoulos K; Bagli H; Peschos D; Psilas K; Agnantis NJ
    Int J Clin Pract; 2005 Oct; 59(10):1157-61. PubMed ID: 16178982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy.
    Kauffmann DJ; van Meurs JC; Mertens DA; Peperkamp E; Master C; Gerritsen ME
    Invest Ophthalmol Vis Sci; 1994 Mar; 35(3):900-6. PubMed ID: 8125753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.
    Kon CH; Occleston NL; Aylward GW; Khaw PT
    Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indicators of oxidative tissue damage and inflammatory activity in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
    Augustin AJ; Spitznas M; Koch F; Grus F; Böker T
    Ger J Ophthalmol; 1995 Jan; 4(1):47-51. PubMed ID: 7728110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy.
    Sydorova M; Lee MS
    Ophthalmic Res; 2005; 37(4):188-90. PubMed ID: 15990461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy.
    Limb GA; Chignell AH; Cole CJ; Green WT; Webster L; Hollifield RD; Dumonde DC
    Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):1043-8. PubMed ID: 9113001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of thrombospondin-2 as a marker in proliferative diabetic retinopathy.
    Abu El-Asrar AM; Nawaz MI; Ola MS; De Hertogh G; Opdenakker G; Geboes K
    Acta Ophthalmol; 2013 May; 91(3):e169-77. PubMed ID: 23387388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological biomarkers of the vitreous responsible for proliferative alteration in the different forms of retinal detachment.
    Balogh A; Milibák T; Szabó V; Nagy ZZ; Kaarniranta K; Resch MD
    BMC Ophthalmol; 2020 Dec; 20(1):491. PubMed ID: 33371882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between ficolin-3 and vascular endothelial growth factor-to-pigment epithelium-derived factor ratio in the vitreous of eyes with proliferative diabetic retinopathy.
    Zheng B; Li T; Chen H; Xu X; Zheng Z
    Am J Ophthalmol; 2011 Dec; 152(6):1039-43. PubMed ID: 21851923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated erythropoietin in vitreous of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
    Wang ZY; Shen LJ; Zhao KK; Song ZM; Qu J
    Ophthalmic Res; 2009; 42(3):138-40. PubMed ID: 19602911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy.
    Mohan N; Monickaraj F; Balasubramanyam M; Rema M; Mohan V
    J Diabetes Complications; 2012; 26(5):435-41. PubMed ID: 22699109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiogenin levels in the vitreous from patients with proliferative diabetic retinopathy.
    Ozaki H; Hayashi H; Oshima K
    Ophthalmic Res; 1996; 28(6):356-60. PubMed ID: 9032794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy.
    Kakehashi A; Inoda S; Mameuda C; Kuroki M; Jono T; Nagai R; Horiuchi S; Kawakami M; Kanazawa Y
    Diabetes Res Clin Pract; 2008 Mar; 79(3):438-45. PubMed ID: 18053608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological changes in the vitreoretinal junction 1: epiretinal membrane formation.
    Snead DR; James S; Snead MP
    Eye (Lond); 2008 Oct; 22(10):1310-7. PubMed ID: 18344963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.